672 related articles for article (PubMed ID: 30077614)
1. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J
Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
[TBL] [Abstract][Full Text] [Related]
3. CHOROIDAL THICKNESS CHANGES IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION WITH INTRAVITREAL BEVACIZUMAB.
Roohipoor R; Sharifian E; Ghassemi F; Riazi-Esfahani M; Karkhaneh R; Fard MA; Zarei M; Modjtahedi BS; Moghimi S
Retina; 2016 Oct; 36(10):1997-2005. PubMed ID: 27046456
[TBL] [Abstract][Full Text] [Related]
4. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
[TBL] [Abstract][Full Text] [Related]
5. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
[TBL] [Abstract][Full Text] [Related]
6. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.
Sun JK; Glassman AR; Beaulieu WT; Stockdale CR; Bressler NM; Flaxel C; Gross JG; Shami M; Jampol LM;
Ophthalmology; 2019 Jan; 126(1):87-95. PubMed ID: 30096354
[TBL] [Abstract][Full Text] [Related]
7. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
[TBL] [Abstract][Full Text] [Related]
8. Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections.
Obeid A; Gao X; Ali FS; Talcott KE; Aderman CM; Hyman L; Ho AC; Hsu J
Ophthalmology; 2018 Sep; 125(9):1386-1392. PubMed ID: 29606377
[TBL] [Abstract][Full Text] [Related]
9. Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.
Messias K; Barroso RM; Jorge R; Messias A
Doc Ophthalmol; 2018 Oct; 137(2):121-129. PubMed ID: 30209775
[TBL] [Abstract][Full Text] [Related]
10. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.
Filho JA; Messias A; Almeida FP; Ribeiro JA; Costa RA; Scott IU; Jorge R
Acta Ophthalmol; 2011 Nov; 89(7):e567-72. PubMed ID: 21726427
[TBL] [Abstract][Full Text] [Related]
11. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
[TBL] [Abstract][Full Text] [Related]
12. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy.
Ernst BJ; García-Aguirre G; Oliver SC; Olson JL; Mandava N; Quiroz-Mercado H
Acta Ophthalmol; 2012 Nov; 90(7):e573-4. PubMed ID: 22405048
[No Abstract] [Full Text] [Related]
14. Anti-Vascular Endothelial Growth Factor and Panretinal Photocoagulation Use after Protocol S for Proliferative Diabetic Retinopathy.
Azad AD; Chen EM; Hinkle J; Rayess N; Wu D; Eliott D; Mruthyunjaya P; Parikh R
Ophthalmol Retina; 2021 Feb; 5(2):151-159. PubMed ID: 32693033
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment.
Dong F; Yu C; Ding H; Shen L; Lou D
Medicine (Baltimore); 2016 Feb; 95(8):e2731. PubMed ID: 26937902
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Eyes With Diabetic Macular Edema That Are Lost to Follow-up After Anti-Vascular Endothelial Growth Factor Therapy.
Matsunaga DR; Salabati M; Obeid A; Wibbelsman TD; Wu C; Mahmoudzadeh R; Ojalvo I; Bilello J; Sivalingam A; Ho AC; Chiang A; Hsu J
Am J Ophthalmol; 2022 Jan; 233():1-7. PubMed ID: 34283979
[TBL] [Abstract][Full Text] [Related]
18. Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy.
Gross JG; Glassman AR; Klein MJ; Jampol LM; Ferris FL; Bressler NM; Beck RW
JAMA Ophthalmol; 2017 Jun; 135(6):672-673. PubMed ID: 28492921
[TBL] [Abstract][Full Text] [Related]
19. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
Glassman AR; Wells JA; Josic K; Maguire MG; Antoszyk AN; Baker C; Beaulieu WT; Elman MJ; Jampol LM; Sun JK
Ophthalmology; 2020 Sep; 127(9):1201-1210. PubMed ID: 32402554
[TBL] [Abstract][Full Text] [Related]
20. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial.
Beaulieu WT; Bressler NM; Melia M; Owsley C; Mein CE; Gross JG; Jampol LM; Glassman AR;
Am J Ophthalmol; 2016 Oct; 170():206-213. PubMed ID: 27523491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
